Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 5
2004 5
2005 3
2006 1
2007 2
2008 4
2009 2
2010 4
2011 5
2012 2
2013 6
2014 7
2015 4
2016 8
2017 2
2018 7
2019 9
2020 16
2021 13
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean tuna mutism (1 results)?
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ. Verkleij CPM, et al. Among authors: mutis t. Blood Adv. 2021 Apr 27;5(8):2196-2215. doi: 10.1182/bloodadvances.2020003805. Blood Adv. 2021. PMID: 33890981 Free PMC article.
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Katsarou A, Sjöstrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, Nianias A, Ruiter R, Poels R, Sarkar I, Patankar YR, Merino E, Reijmers RM, Frerichs KA, Yuan H, de Bruijn J, Stroopinsky D, Avigan D, van de Donk NWCJ, Zweegman S, Mutis T, Sadelain M, Groen RWJ, Themeli M. Katsarou A, et al. Among authors: mutis t. Sci Transl Med. 2021 Dec 8;13(623):eabh1962. doi: 10.1126/scitranslmed.abh1962. Epub 2021 Dec 8. Sci Transl Med. 2021. PMID: 34878825 Free PMC article.
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DRAI, Hijmering NJ, van Essen HF, de Jong D, Chamuleau MED, Zweegman S, Breij ECW, Roemer MGM, Mutis T. van der Horst HJ, et al. Among authors: mutis t. Blood Cancer J. 2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6. Blood Cancer J. 2021. PMID: 33602901 Free PMC article.
Tumour Escape from CAR-T Cells.
Rasche L, Vago L, Mutis T. Rasche L, et al. Among authors: mutis t. 2022 Feb 7. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 4. 2022 Feb 7. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 4. PMID: 36122074 Free Books & Documents. Review.
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK. Krejcik J, et al. Among authors: mutis t. Blood. 2016 Jul 21;128(3):384-94. doi: 10.1182/blood-2015-12-687749. Epub 2016 May 24. Blood. 2016. PMID: 27222480 Free PMC article. Clinical Trial.
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. de Weers M, et al. Among authors: mutis t. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. J Immunol. 2011. PMID: 21187443 Clinical Trial.
Immunotherapy in myeloma: how far have we come?
Franssen LE, Mutis T, Lokhorst HM, van de Donk NWCJ. Franssen LE, et al. Among authors: mutis t. Ther Adv Hematol. 2019 Jan 18;10:2040620718822660. doi: 10.1177/2040620718822660. eCollection 2019. Ther Adv Hematol. 2019. PMID: 30719268 Free PMC article. Review.
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.
Verkleij CPM, Frerichs KA, Broekmans MEC, Duetz C, O'Neill CA, Bruins WSC, Homan-Weert PM, Minnema MC, Levin MD, Broijl A, Bos GMJ, Kersten MJ, Klein SK, Shikhagaie MM, Casneuf T, Abraham Y, Smets T, Vanhoof G, Cortes-Selva D, van Steenbergen L, Ramos E, Verona RI, Krevvata M, Sonneveld P, Zweegman S, Mutis T, van de Donk NWCJ. Verkleij CPM, et al. Among authors: mutis t. Hemasphere. 2023 May 2;7(5):e881. doi: 10.1097/HS9.0000000000000881. eCollection 2023 May. Hemasphere. 2023. PMID: 37153876 Free PMC article.
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138.
van der Schans JJ, Wang Z, van Arkel J, van Schaik T, Katsarou A, Ruiter R, Baardemans T, Yuan H, de Bruijn J, Zweegman S, van de Donk NWCJ, Groen RWJ, Themeli M, Mutis T. van der Schans JJ, et al. Among authors: mutis t. Clin Cancer Res. 2023 Oct 13;29(20):4219-4229. doi: 10.1158/1078-0432.CCR-23-0132. Clin Cancer Res. 2023. PMID: 37527004
Targeted Therapy With Immunoconjugates for Multiple Myeloma.
Bruins WSC, Zweegman S, Mutis T, van de Donk NWCJ. Bruins WSC, et al. Among authors: mutis t. Front Immunol. 2020 Jun 19;11:1155. doi: 10.3389/fimmu.2020.01155. eCollection 2020. Front Immunol. 2020. PMID: 32636838 Free PMC article. Review.
105 results